A study to characterise the safety, tolerability and efficacy of LY4170156 in subjects with advanced solid tumors
LOXO-FRA-24001
Phase 1 other active
Quick answer
A study to characterise the safety, tolerability and efficacy of LY4170156 in subjects with advanced solid tumors for Ovarian cancer, endometrial cancer, cervical cancer, non-small cell lung cancer, triple-negative breast cancer, pancreatic cancer and colorectal cancer. is a Phase 1 program (other) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly Co.
- Indication
- Ovarian cancer, endometrial cancer, cervical cancer, non-small cell lung cancer, triple-negative breast cancer, pancreatic cancer and colorectal cancer.
- Phase
- Phase 1
- Modality
- other
- Status
- active